Inhibitors of glycogen synthase kinase-3: Future therapy for unmet medical needs?

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 10, 2002, Pages 1527-1536

  Dorronsoro, Isabel ^a   Castro, Ana ^a   Martinez, Ana ^a  

^a Neuropharma SA   (Spain)

Author keywords

Alzheimer's disease; Cancer; Glycogen synthase kinase 3 (GSK 3) inhibitors; Inflammation; Type II diabetes

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; ANTIGEN P24; ANTISENSE OLIGONUCLEOTIDE; CHOLINESTERASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; INDIRUBIN; LITHIUM; MALEIMIDE DERIVATIVE; MUSCARINIC AGENT; PAULLONE DERIVATIVE; PEPTIDE DERIVATIVE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE; PYRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRIMIDINONE DERIVATIVE; STAUROSPORINE DERIVATIVE; THIADIAZOLE DERIVATIVE; THIAZOLE DERIVATIVE; TRIAZINE DERIVATIVE; TROGLITAZONE; UNINDEXED DRUG; VALPROIC ACID;

ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; CANCER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INDUSTRY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; INFLAMMATORY DISEASE; MANIC DEPRESSIVE PSYCHOSIS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; STROKE; STRUCTURE ANALYSIS;

EID: 0036799220     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.10.1527     Document Type: Review

References (33)

1. FRAME S, COHEN P: GSK-3 takes centre stage more than 20 years after its discovery. Biochem. J. (2001) 359:1-16.
2. LAU KE MILLER CC, ANDERTON BH, SHAW PC: Expression analysis of glycogen synthase kinase-3 in human tissues. J. Pept. Res. (1999) 54:85-91.
3. MUKAI F, ISHIGURO K, SANO Y, FUJITA SC: Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase-3β. J. Neurochem. (2002) 81:1073-1083.
4. GRIMES CA, JOPE RS: The multifaceted roles of glycogen synthase kinasc-3β in cellular signalling. Prog. Neurobiol. (2001) 65:391-426.
5. LUCAS JJ, HERNANDEZ F, GOMEZ-RAMOS P, MORAN MA, HEN R. AVILA J: Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-30 conditional transgenic mice. EMBO J. (2001) 20:27-39.
6. KAYTOR MD, ORR HT: The GSK-3β signalling cascade and neurodegenerative disease. Curr. Opin. Neurob. (2002) 12:275-278.
7. CASTRO A, MARTINEZ A: Inhibition of tau phosphorylation: a new therapeutic strategy for the treatment of Alzheimer's disease and other neurodegenerative disorders. Exp. Opin. Ther. Patents (2000) 10:1519-1527.
8. LI X, BIJUR GN, JOPE RS: Glycogen synthase kinase-3β, mood stabilizers, and neuroprotection. Bipolar Disord. (2002) 4:37-144.
9. MARTINEZ A, CASTRO A, DORRONSORO I, ALONSO M: Glycogen synthase kinase-3β (GSK-3β) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer and inflammation. Med. Res. Rev. (2002) 22:373-384.
10. COHEN P, FRAME S: The renaissance of GSK-3. Nat. Rev. (2001) 2:769-776.
11. YOST C, FARR GH, PIERCE SB, FERKEY DM, CHEN MM, KIMELMAN D: GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell (1998) 93:1031-1041.
12. PEREZ C, VAZQUEZ J, AVILA J, MORENO FJ. P24, a glycogen synthase ldnase-3 (GSK-3) inhibitor. Biochim. Biophys. Acta (2002) 1586:113-122.
13. TER HAAR E, COLL JT, AUSTEN DA, HSIAO HM, SWENSON L, JAIN J: Structure of GSK-3β reveals a primed phosphorylation mechanism. Nat. Struc. Biol (2001) 8:593-596.
14. DAJANI R, FRASER E, ROE SM et al.: Crystal structure of glycogen synthase kinase-3β: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell (2001) 105:721-732.
15. BAX B, CARTER PS, LEWIS C et al.: The structure of phosphorylated GSK-3β complexed with a peptide, FRATtide, that inhibits β-catenin phosphorylation. Structure (2001) 9:1143-1152.
16. HERS I, TAVARE JM, DENTON RM: The protein kinase C inhibitors bisindolylmaleimide I (GF109203X) and IX (Ro 31-8220) are potent inhibitors of glycogen kinase-3 activity. FEBS Lett, (1990) 460:433-436.
17. SMITH DG, BUFFET M, FENWICK AE et al.: 3-Anilino-4-arylmalcimides: Potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. (2001) 11:635-639.
18. COGHLAN MP, CULBERT AA, CROSS DAE et al.: Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol, (2000) 7:793-803.
19. CROSS DAE, CUBERT AA, CHALMERS KA, FACCI L, SKAPER SD, REITH AD: Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protects primary neurones from death. J. Neurochem. (2001) 77:94-102.
20. BARNES PJ: Cyrokine modulators as novel therapies for asthma. Annu. Rev. Pharmaco. Toxico. (2002) 42:81-98.
21. MEIJER L, THUNNISSEN AM, WHITE AW et al.: Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenaldisine, a marine sponge constituent. Chem. Biol. (2000) 7:51-63.
22. BRETON JJ, CHABOT-FLETCHER MC: The natural product hymenaldisine inhibits interleukin-8 production in U937 cells by inhibition of nuclear factor-KB. J. Pharmacol. Exp. Ther. Patents (1997) 282:459-466.
23. ZAHAREVITZ DW, GUSSIO R. LEOST M et al.: Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. (1999) 1:60-67.
24. LECLERC S, GARNIER M, HOESSEL R et al.: Indirubins inhibit glycogen synthase kinase-3β and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors. J. Biol. Chem. (2001) 276:251-260.
25. MARTINEZ A, ALONSO M, CASTRO A, PEREZ C, MORENO FJ: First non-ATP competitive glycogen synthase kinase-3β (GSK-3β) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease J. Med. Chem. (2002) 45(6):1292-1299.
26. MARTINEZA, CASTRO A, CARDELUS I, LLENAS J, PALACIOS JM: Arylimino-1,2,4-thidiazolidinones: a new family of potassium channel openers. Bioorg. Med. Chem. (1997) 5:1275-1283.
27. MARTINEZ A, ALONSO D, CASTRO A et al.: Synthesis and potential muscarinic receptor binding and antioxidant properties of 3-(thiadiazolyl)pyridine 1-oxide compounds. Arch. Pharm. (1999) 331-191-194.
28. MARTINEZ A, FERNÁNDEZ E, CASTRO A et al.: N-benzylpiperidine derivatives of 1,2,4-thiadiazohdinone as new acetylcholinesterase inhibitors. Eur. J. Med. Chem: (2000) 35:913-922.
29. CASTRO A, CONDE S, RODRIGUEZ-FRANCO MI, MARTINEZ A. Noncholinergic pharmacotharapy approaches to the future treatment of Alzheimer's disease. Mini Rev. Med. Chem. (2002) 2:37-50.
30. MACCIONI RB, MUÑOZ JP, BARBEITO L: The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch. Med. Res. (2001) 32:367-381.
31. GÖTZ J: Tau and transgenic animal models. Brain Res. Rev. (2001) 35:266-286.
32. HERNANDEZ F, LIM F, LUCAS JJ et al.: Transgenic mouse models with tau pathology to test therapeutic agents for Alzheimer's disease. Mini Rev. Med. Chem. (2002) 2:51-58.
33. ALI A, HOEFLICH KP, WOODGETT JR: Glycogen synthase kinase-3: Properties, functions and regulation. Chem. Rev. (2001) 101:2527-2540.